Literature DB >> 3407674

Acyclovir in Pregnancy Registry. An observational epidemiologic approach.

E B Andrews1, H H Tilson, B A Hurn, J F Cordero.   

Abstract

Observational epidemiologic methods are being used to evaluate the safety of acyclovir in pregnancy. An essential component of this research is the establishment of a baseline expectation of pregnancy outcomes among women with herpes not receiving acyclovir. Continuing studies will be described in this report. To supplement these structured studies, an international case registration study was established. Through the Acyclovir in Pregnancy Registry, all cases of reported prenatal exposures to acyclovir are tracked to ascertain maternal exposure, risk factor, and pregnancy outcome information. The reports originate in all countries where oral acyclovir is marketed; data consolidation and analysis are coordinated at Burroughs Wellcome Co. with the assistance of a government/industry advisory panel. This presentation summarizes provisional data from the prospective reports, including trimester of exposure and reported outcomes of pregnancy. The total number of monitored pregnancies remains too small to support conclusions about the safety of acyclovir during pregnancy at this point. The potential for the registry and other epidemiologic studies to address the safety-in-pregnancy question will be discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3407674

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Preventing neonatal herpes?

Authors:  D E Mercey; A Mindel
Journal:  Genitourin Med       Date:  1991-02

Review 2.  Herpes simplex virus infections of women and their offspring: implications for a developed society.

Authors:  R J Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 3.  Genital herpes. A guide to pharmacological therapy.

Authors:  A de Ruiter; R N Thin
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.